Company intelligence / Profile preview

EPOS-Iasis

Nicosia, Cyprus

Ownership: Private
Development stage: Other

Overview

EPOS-Iasis has pioneered multimodal imaging, nanotheranostics, and cell-based technologies. It has developed prototype systems for preclinical molecular imaging (e.g., mCT-3DOI-FMT), with ongoing translational research bridging molecular imaging and therapeutics for oncology and inflammatory diseases. Key prototypes include molecular probes for EGFR and innovative drug delivery systems for brain tumors.

Therapeutic areas: OncologyGastroenterology
Modalities: NanoparticleSmall moleculeMolecular probeBiologicTheranostic agent
Industry: Biotech

Drug pipeline

1 asset

BRAIN-THROUGH

Preclinical

Partnerships

National Medical and Public Health Services (Cyprus)Brain Tumour Patient AssociationAcademic consortia in FP7, H2020, MDCAs, FETOpenIndustrial partners for production and testing (unnamed)

Beyond the preview

Go deeper on EPOS-Iasis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPOS-Iasis.

Explore the full profile